On Thursday 10 December 2026 K. Bals will defend the doctoral thesis titled: Unraveling the Mechanisms Underlying Retinal Hemangioblastoma in Von Hippel–Lindau Disease
- Promotor
- Co-promotor
- Date
- Thursday 10 Dec 2026, 13:00 - 14:30
- Type
- PhD defence
- Space
- Senate Hall
- Building
- Erasmus Building
- Location
- Campus Woudestein
Below is a brief summary of the dissertation:
Von Hippel–Lindau (VHL) syndrome is a rare hereditary tumor syndrome caused by pathogenic variants in the VHL gene. Loss of the VHL tumor suppressor protein results in abnormal activation of hypoxia-inducible factor (HIF) signaling, promoting the development of highly vascular tumors in multiple organs. Retinal hemangioblastomas (RHs) are among the most common and earliest manifestations of VHL syndrome, affecting approximately 70% of patients. Despite their clinical importance, the mechanisms underlying RH development remain poorly understood, largely due to the limited availability of tumor tissue and the lack of suitable experimental models.
This thesis investigates the molecular and cellular mechanisms driving RH formation and develops new approaches to study disease development and therapeutic opportunities. By integrating whole-genome sequencing, transcriptomic analyses, clinical data, and functional studies, this work demonstrates that loss of VHL function is sufficient to establish the molecular program underlying RH development, without evidence for additional recurrent oncogenic drivers. Furthermore, this research provides insight into how specific VHL variants influence protein function and clinical outcomes.
To overcome the limitations of studying rare retinal tumors, human induced pluripotent stem cell (iPSC)-based models were developed to generate retinal vascular cell types and investigate early disease processes in a controlled environment. These models provide a platform to study tumor formation and evaluate potential targeted therapies.
Together, the findings of this thesis improve our understanding of VHL-associated retinal tumors and provide new tools for precision medicine, supporting future development of personalized treatments for patients with VHL syndrome.
- More information
The public defence will begin exactly at 13.00 hrs. The doors will be closed once the public defence starts, latecomers may be able to watch on the screen outside. There is no possibility of entrance during the first part of the ceremony. Due to the solemn nature of the ceremony, we recommend that you do not take children under the age of 6 to the first part of the ceremony.
A live stream link has been provided to the candidate.
